A Phase 1 Study of LY2523355 in Patients With Solid Cancer
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0
Yes
Senior Manager
Study Director
Kyowa Hakko Kirin
Japan: Ministry of Health, Labor and Welfare
2523355-001
NCT01358019
May 2011
January 2013
Name | Location |
---|